Chapter review

Fitzgerald PMHNP board review. ch09. Anxiety Disorders. This is drive 7 of 7. When I say Pause. Answer. wait, then I will give the answer. New section. Pharmacotherapy and psychotherapy pearls, benzo traps, and safety alerts. Topic. Fitzgerald Sample Question: Benzo Onset. Bottom Line Summary. * **Onset of Action**: Oral benzodiazepines generally take effect within 15 to 30 minutes, but **diazepam** has the fastest onset of action due to high lipophilicity, combined with the longest half-life of 20 to 80 hours [1, 2]. * **High-Risk Short-Acting Agent**: **Alprazolam** possesses a rapid onset and the shortest half-life of 12 to 15 hours, predisposing patients to rapid tolerance, severe rebound anxiety, and rapid withdrawal onset [1-3]. * **Dosing Equivalencies**: Standardized potency equivalencies require knowing that **alprazolam** 0.5 mg equals **clonazepam** 0.25 mg, **diazepam** 5 mg, and **lorazepam** 0.75 mg to 1 mg [2, 4]. * **Withdrawal Onset Timelines**: Withdrawal symptoms manifest within 1 to 2 days for short-acting benzodiazepines and within 5 to 10 days for long-acting benzodiazepines source 5. * **Alprazolam Tapering Rules**: Outpatient tapering of **alprazolam** must proceed slowly at a rate no faster than 0.25 mg per week to prevent severe withdrawal, delirium, and seizures [6, 7]. * **Diazepam Substitution Strategy**: An evidence-based alternative taper substitutes an equivalent total daily dose of **diazepam**, followed by a dose reduction of 10% to 20% every 1 to 2 weeks as tolerated [6, 7]. * **Rebound vs Relapse**: Rebound anxiety emerges hours to days post-discontinuation and is more intense than pre-treatment anxiety, whereas relapse anxiety develops weeks to months later as baseline symptoms return source 3. * **First-Line Indication**: **First-line** long-term treatment for anxiety disorders consists of SSRIs, SNRIs, or CBT, whereas benzodiazepines are limited to short-term bridging for 2 to 3 weeks during initial antidepressant titration [8, 9]. High-Yield Concept Review: Benzodiazepine Onset and Pharmacokinetics. Spoken Teaching and Comparative Analysis. All primary oral benzodiazepines share a rapid absorption profile, producing clinical onset within 15 to 30 minutes [1, 2]. What separates these agents on board exams is lipophilicity, elimination half-life, and metabolic clearance [1, 2]. **Diazepam** enters the central nervous system fastest because of its high lipid solubility, but its prolonged elimination half-life of 20 to 80 hours leads to active metabolite accumulation [1, 2]. In contrast, **alprazolam** pairs rapid onset with a short half-life of 12 to 15 hours, causing inter-dose breakthrough anxiety and intense withdrawal triggers [1-3]. **Lorazepam** exhibits a short to intermediate half-life of 10 to 20 hours, making it preferred in hepatic impairment because it undergoes direct glucuronidation without active hepatic CYP450 metabolites [2, 4]. **Clonazepam** provides an intermediate to long half-life of 18 to 50 hours, offering smoother serum levels for panic coverage [2, 4]. Potency conversions are highly testable. Clinical equivalency benchmarks demonstrate that **alprazolam** 0.5 mg provides equivalent GABA-A receptor modulation to **clonazepam** 0.25 mg, **diazepam** 5 mg, and **lorazepam** 0.75 mg to 1 mg [2, 4]. Key Clinical Signposts. * **Safety alert**: Benzodiazepine withdrawal mechanism targets GABA receptors and directly mirrors alcohol withdrawal [5, 10]. Abrupt cessation triggers severe autonomic hyperarousal, diaphoresis, tremors, tachycardia, delirium, coma, and potentially fatal grand mal seizures [10, 11]. * **Board trap**: Choosing to stop short-acting benzodiazepines abruptly when a patient reports side effects or asks to discontinue therapy. Never stop short-acting agents suddenly. Taper **alprazolam** by no more than 0.25 mg per week, or substitute an equivalent dose of **diazepam** before tapering [6, 7]. * **Board trap**: Prescribing benzodiazepines as long-term monotherapy or using them in post-traumatic stress disorder (PTSD). Clinical guidelines specifically flag benzodiazepines as ineffective and harmful in PTSD [12, 13]. * **First-line**: **First-line** maintenance pharmacotherapy for generalized anxiety disorder, panic disorder, and social anxiety disorder consists of SSRIs or SNRIs [8, 14, 15]. Benzodiazepines are restricted to brief 2 to 3 week bridging during initial antidepressant setup [8, 9]. Fitzgerald Sample Test Question. Question 16. A 32-year-old female with generalized anxiety disorder has been taking **alprazolam** 1 mg three times daily for six months. When considering discontinuation, which of the following statements is false? source 16 A. Rebound anxiety symptoms can occur hours to days following discontinuation. B. Withdrawal symptoms are generally considered minimal and non-life threatening. C. Dosage should be tapered no more than 0.25 mg per week. D. An equivalent dose of **diazepam** can be substituted prior to tapering dose. Pause. Answer: B source 11. Key Clue. The question stem describes a patient on chronic, high-dose **alprazolam** (3 mg total daily) and asks you to identify the false statement regarding discontinuation source 16. Best Answer. B. Withdrawal symptoms are generally considered minimal and non-life threatening source 11. Why It Is Correct. Statement B is false because benzodiazepine withdrawal involves profound GABA receptor down-regulation [10, 11]. Abrupt or rapid cessation can cause severe, life-threatening withdrawal complications including delirium, autonomic collapse, and grand mal seizures [10, 11]. Because statement B is factually incorrect, it is the keyed correct response for this item source 11. Why the Other Choices Are Wrong. * **A**: Incorrect choice because the statement is true. Rebound anxiety frequently occurs hours to days after stopping short-acting agents and is often more severe than the baseline anxiety disorder [3, 11]. * **C**: Incorrect choice because the statement is true. To avoid withdrawal seizures and delirium, **alprazolam** must be tapered gradually at a rate not exceeding 0.25 mg per week [6, 17]. * **D**: Incorrect choice because the statement is true. Converting the patient to an equivalent dose of long-acting **diazepam** provides stable plasma levels and simplifies a safe step-down taper [6, 17]. Test-Taking Pearl. When a board question asks for the false, least appropriate, or unindicated choice, systematically mark each true clinical statement as wrong until only the factually incorrect option remains [11, 16]. Next. End of this drive.